DWP712 not checked
Daewoong Pharmaceutical Co. LTD.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Glabellar Lines
- Main trialPhase 3
- “To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines”In the company’s words, NCT07013279 on ClinicalTrials.gov
- Given with
- Botox (Allergan)Other companies’ drugs in its trials
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 31 Dec 2025 | Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines | |
| Phase 1Completed | 26 Feb 2024 | Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026